| 1 | Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein | 12.4 | 45 | Citations (PDF) |
| 2 | Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage | 12.4 | 26 | Citations (PDF) |
| 3 | Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease | 7.4 | 10 | Citations (PDF) |
| 4 | TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease | 38.2 | 32 | Citations (PDF) |
| 5 | A microtubule stabilizer ameliorates protein pathogenesis and neurodegeneration in mouse models of repetitive traumatic brain injury | 13.1 | 9 | Citations (PDF) |
| 6 | α-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice | 14.1 | 16 | Citations (PDF) |
| 7 | Tau interactome maps synaptic and mitochondrial processes associated with neurodegenerationCell, 2022, 185, 712-728.e14 | 35.1 | 138 | Citations (PDF) |
| 8 | Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology | 5.0 | 5 | Citations (PDF) |
| 9 | Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization | 5.1 | 12 | Citations (PDF) |
| 10 | Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis | 5.1 | 8 | Citations (PDF) |
| 11 | Fluent molecular mixing of Tau isoforms in Alzheimer’s disease neurofibrillary tangles | 14.1 | 33 | Citations (PDF) |
| 12 | In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics | 7.9 | 33 | Citations (PDF) |
| 13 | Evaluation of the Structure–Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-<i>a</i>]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies | 6.9 | 22 | Citations (PDF) |
| 14 | Distinct brain‐derived TDP‐43 strains from FTLD‐TDP subtypes induce diverse morphological TDP‐43 aggregates and spreading patterns <i>in vitro</i> and <i>in vivo</i> | 3.4 | 30 | Citations (PDF) |
| 15 | Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD Samples | 4.1 | 18 | Citations (PDF) |
| 16 | Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor | 11.3 | 27 | Citations (PDF) |
| 17 | Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery | 5.1 | 29 | Citations (PDF) |
| 18 | LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons | 3.7 | 5 | Citations (PDF) |
| 19 | Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice | 5.1 | 20 | Citations (PDF) |
| 20 | The development and convergence of co-pathologies in Alzheimer’s diseaseBrain, 2021, 144, 953-962 | 8.9 | 101 | Citations (PDF) |
| 21 | Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor | 3.8 | 50 | Citations (PDF) |
| 22 | α-Synuclein modulates tau spreading in mouse brains | 8.1 | 55 | Citations (PDF) |
| 23 | Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration | 2.1 | 5 | Citations (PDF) |
| 24 | Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro | 5.1 | 39 | Citations (PDF) |
| 25 | AD-linked R47H-<i>TREM2</i>mutation induces disease-enhancing microglial states via AKT hyperactivation | 13.1 | 65 | Citations (PDF) |
| 26 | Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease | 7.9 | 30 | Citations (PDF) |
| 27 | Transmission of tauopathy strains is independent of their isoform composition | 14.1 | 126 | Citations (PDF) |
| 28 | Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult | 12.8 | 92 | Citations (PDF) |
| 29 | Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology | 12.8 | 152 | Citations (PDF) |
| 30 | Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease | 5.2 | 33 | Citations (PDF) |
| 31 | Characterization of tau binding by gosuranemab | 5.2 | 44 | Citations (PDF) |
| 32 | Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo | 7.9 | 42 | Citations (PDF) |
| 33 | Defining and predicting transdiagnostic categories of neurodegenerative disease | 18.8 | 24 | Citations (PDF) |
| 34 | Modulating TRADD to restore cellular homeostasis and inhibit apoptosis | 40.1 | 76 | Citations (PDF) |
| 35 | Correction of microtubule defects within Aβ plaque‐associated dystrophic axons results in lowered Aβ release and plaque deposition | 0.7 | 13 | Citations (PDF) |
| 36 | Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo | 1.9 | 9 | Citations (PDF) |
| 37 | Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease | 14.2 | 21 | Citations (PDF) |
| 38 | Cell-to-Cell Transmission of Tau and α-Synuclein | 10.0 | 102 | Citations (PDF) |
| 39 | Distribution patterns of tau pathology in progressive supranuclear palsy | 7.9 | 254 | Citations (PDF) |
| 40 | Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer’s diseaseBrain, 2020, 143, 1572-1587 | 8.9 | 52 | Citations (PDF) |
| 41 | The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates | 3.8 | 50 | Citations (PDF) |
| 42 | Protein transmission in neurodegenerative disease | 9.2 | 391 | Citations (PDF) |
| 43 | Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice | 5.8 | 14 | Citations (PDF) |
| 44 | Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex | 7.9 | 4 | Citations (PDF) |
| 45 | Synthesis and characterization of high affinity fluorogenic α-synuclein probes | 4.2 | 27 | Citations (PDF) |
| 46 | Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays | 2.3 | 12 | Citations (PDF) |
| 47 | Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia | 4.1 | 166 | Citations (PDF) |
| 48 | Human tau pathology transmits glial tau aggregates in the absence of neuronal tau | 8.1 | 73 | Citations (PDF) |
| 49 | Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease | 9.1 | 303 | Citations (PDF) |
| 50 | Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders | 6.6 | 90 | Citations (PDF) |
| 51 | C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy | 7.9 | 46 | Citations (PDF) |
| 52 | Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis | 12.4 | 187 | Citations (PDF) |
| 53 | Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer’s disease patient brain samples | 7.9 | 64 | Citations (PDF) |
| 54 | Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation | 2.3 | 129 | Citations (PDF) |
| 55 | Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changesBrain, 2019, 142, 3565-3579 | 8.9 | 85 | Citations (PDF) |
| 56 | Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α-Syn) Pathology in Synthetic α-Syn Fibril-Induced Mouse Models of Synucleinopathy | 1.9 | 49 | Citations (PDF) |
| 57 | Genetic predictors of survival in behavioral variant frontotemporal degeneration | 1.3 | 14 | Citations (PDF) |
| 58 | TREM2 function impedes tau seeding in neuritic plaques | 12.4 | 195 | Citations (PDF) |
| 59 | α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies | 1.9 | 193 | Citations (PDF) |
| 60 | Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies | 5.1 | 19 | Citations (PDF) |
| 61 | α-Synuclein (αSyn) Preformed Fibrils Induce Endogenous αSyn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons | 3.7 | 69 | Citations (PDF) |
| 62 | eIF4B and eIF4H mediate GR production from expanded G4C2 in a Drosophila model for C9orf72-associated ALS | 5.1 | 36 | Citations (PDF) |
| 63 | Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau) | 5.1 | 28 | Citations (PDF) |
| 64 | LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice | 5.1 | 36 | Citations (PDF) |
| 65 | Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils | 0.0 | 20 | Citations (PDF) |
| 66 | Transmission of α-synuclein seeds in neurodegenerative disease: recent developments | 3.5 | 81 | Citations (PDF) |
| 67 | Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease | 5.1 | 98 | Citations (PDF) |
| 68 | Neuroimmune interactions in Alzheimer's disease—New frontier with old challenges? | 1.0 | 15 | Citations (PDF) |
| 69 | Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain | 13.1 | 29 | Citations (PDF) |
| 70 | Mechanisms of Cell-to-Cell Transmission of Pathological Tau | 14.3 | 177 | Citations (PDF) |
| 71 | Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice | 5.2 | 25 | Citations (PDF) |
| 72 | A “Clickable” Photoconvertible Small Fluorescent Molecule as a Minimalist Probe for Tracking Individual Biomolecule Complexes | 15.7 | 40 | Citations (PDF) |
| 73 | Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders | 14.3 | 182 | Citations (PDF) |
| 74 | Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy | 12.4 | 206 | Citations (PDF) |
| 75 | Measurements of auto‐antibodies to α‐synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease | 4.0 | 52 | Citations (PDF) |
| 76 | Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity | 7.9 | 87 | Citations (PDF) |
| 77 | Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies | 1.9 | 66 | Citations (PDF) |
| 78 | Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology | 7.9 | 133 | Citations (PDF) |
| 79 | Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies | 5.2 | 127 | Citations (PDF) |
| 80 | A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model | 14.2 | 29 | Citations (PDF) |
| 81 | Aberrant activation of non-coding RNA targets of transcriptional elongation complexes contributes to TDP-43 toxicity | 14.1 | 35 | Citations (PDF) |
| 82 | Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo | 14.1 | 166 | Citations (PDF) |
| 83 | Converging Patterns of α-Synuclein Pathology in Multiple System Atrophy | 1.9 | 29 | Citations (PDF) |
| 84 | Sex-specific genetic predictors of Alzheimer’s disease biomarkers | 7.9 | 79 | Citations (PDF) |
| 85 | Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain | 5.1 | 82 | Citations (PDF) |
| 86 | Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents | 3.7 | 160 | Citations (PDF) |
| 87 | Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies | 40.1 | 440 | Citations (PDF) |
| 88 | LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons | 5.1 | 31 | Citations (PDF) |
| 89 | TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading | 8.1 | 158 | Citations (PDF) |
| 90 | Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associatedBrain, 2018, 141, 2181-2193 | 8.9 | 464 | Citations (PDF) |
| 91 | Non-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study | 7.9 | 120 | Citations (PDF) |
| 92 | Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy | 3.8 | 25 | Citations (PDF) |
| 93 | Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies | 2.3 | 119 | Citations (PDF) |
| 94 | Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies | 3.7 | 26 | Citations (PDF) |
| 95 | Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases | 1.9 | 103 | Citations (PDF) |
| 96 | Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs | 5.2 | 77 | Citations (PDF) |
| 97 | GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils | 3.7 | 37 | Citations (PDF) |
| 98 | Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain | 3.7 | 271 | Citations (PDF) |
| 99 | Modeling Parkinson’s disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain | 7.7 | 165 | Citations (PDF) |
| 100 | [PL‐04–02–01]: CELL‐TO‐CELL TRANSMISSION OF PATHOLOGICAL TAU: A POTENTIAL MECHANISM OF DISEASE PROGRESSION IN ALZHEIMER'S AND OTHER TAUOPATHIES | 0.7 | 0 | Citations (PDF) |
| 101 | TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling | 3.9 | 65 | Citations (PDF) |
| 102 | Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies | 8.9 | 142 | Citations (PDF) |
| 103 | Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group | 3.6 | 36 | Citations (PDF) |
| 104 | TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss | 12.8 | 161 | Citations (PDF) |
| 105 | The use of mouse models to study cell-to-cell transmission of pathological tau | 0.0 | 15 | Citations (PDF) |
| 106 | Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration | 5.1 | 34 | Citations (PDF) |
| 107 | Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term | 7.9 | 151 | Citations (PDF) |
| 108 | Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation | 25.6 | 455 | Citations (PDF) |
| 109 | Deep clinical and neuropathological phenotyping of <scp>P</scp>ick disease | 6.6 | 151 | Citations (PDF) |
| 110 | Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons | 3.7 | 72 | Citations (PDF) |
| 111 | P2‐163: Performance Evaluation of New Absorbance‐Based Elisas for Measuring Different Alpha‐Synuclein (A‐SYN) Species in CSF and Plasma | 0.7 | 1 | Citations (PDF) |
| 112 | IC‐P‐186: [<sup>11</sup>C]PBB3 PET Visualizes TAU Aggregates in Patients with FTDP‐17 MAPT Gene Mutation | 0.7 | 2 | Citations (PDF) |
| 113 | The Dynamics and Turnover of Tau Aggregates in Cultured Cells | 2.3 | 60 | Citations (PDF) |
| 114 | Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity | 6.4 | 135 | Citations (PDF) |
| 115 | Cognitive reserve in frontotemporal degeneration | 1.3 | 36 | Citations (PDF) |
| 116 | Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease | 8.1 | 292 | Citations (PDF) |
| 117 | Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy | 3.7 | 56 | Citations (PDF) |
| 118 | O2‐10‐05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease | 0.7 | 0 | Citations (PDF) |
| 119 | Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice | 8.1 | 311 | Citations (PDF) |
| 120 | Therapeutic strategies for the treatment of tauopathies: Hopes and challenges | 0.7 | 94 | Citations (PDF) |
| 121 | Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy | 5.1 | 44 | Citations (PDF) |
| 122 | Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration | 7.9 | 80 | Citations (PDF) |
| 123 | Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice | 5.1 | 14 | Citations (PDF) |
| 124 | Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis | 12.8 | 72 | Citations (PDF) |
| 125 | Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein | 6.4 | 759 | Citations (PDF) |
| 126 | Comparison of strategies for non-perturbing labeling of α-synuclein to study amyloidogenesis | 2.7 | 32 | Citations (PDF) |
| 127 | Conserved Lysine Acetylation within the Microtubule-Binding Domain Regulates MAP2/Tau Family Members | 2.5 | 12 | Citations (PDF) |
| 128 | Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His | 5.1 | 13 | Citations (PDF) |
| 129 | Spreading of pathology in neurodegenerative diseases: a focus on human studies | 10.0 | 598 | Citations (PDF) |
| 130 | Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43 | 7.9 | 192 | Citations (PDF) |
| 131 | Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC’s afferent and efferent connections | 7.9 | 172 | Citations (PDF) |
| 132 | Drosha Inclusions Are New Components of Dipeptide-Repeat Protein Aggregates in FTLD-TDP and ALS<i>C9orf72</i>Expansion Cases | 1.9 | 28 | Citations (PDF) |
| 133 | High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration | 5.1 | 18 | Citations (PDF) |
| 134 | An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice | 3.1 | 38 | Citations (PDF) |
| 135 | Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice | 5.2 | 165 | Citations (PDF) |
| 136 | Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models | 2.5 | 119 | Citations (PDF) |
| 137 | Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin | 2.5 | 36 | Citations (PDF) |
| 138 | Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-oldBrain, 2014, 137, 2578-2587 | 8.9 | 134 | Citations (PDF) |
| 139 | Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia | 1.3 | 25 | Citations (PDF) |
| 140 | Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB | 7.2 | 274 | Citations (PDF) |
| 141 | Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis | 14.3 | 68 | Citations (PDF) |
| 142 | Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) | 7.9 | 237 | Citations (PDF) |
| 143 | Modeling Lewy pathology propagation in Parkinson's disease | 2.4 | 100 | Citations (PDF) |
| 144 | Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes | 2.5 | 196 | Citations (PDF) |
| 145 | Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases | 25.6 | 518 | Citations (PDF) |
| 146 | α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration | 6.4 | 279 | Citations (PDF) |
| 147 | Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins | 5.1 | 27 | Citations (PDF) |
| 148 | Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A<sub>2</sub>)-Receptor Antagonists | 3.6 | 6 | Citations (PDF) |
| 149 | A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank | 0.7 | 163 | Citations (PDF) |
| 150 | Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease | 2.7 | 83 | Citations (PDF) |
| 151 | Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration | 3.4 | 40 | Citations (PDF) |
| 152 | Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine | 7.9 | 216 | Citations (PDF) |
| 153 | Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains | 7.9 | 203 | Citations (PDF) |
| 154 | Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies | 10.0 | 684 | Citations (PDF) |
| 155 | MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications | 3.6 | 34 | Citations (PDF) |
| 156 | Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy | 2.3 | 252 | Citations (PDF) |
| 157 | Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases | 2.1 | 44 | Citations (PDF) |
| 158 | Therapeutic strategies for tau mediated neurodegeneration | 2.0 | 103 | Citations (PDF) |
| 159 | Acetylated Tau Neuropathology in Sporadic and Hereditary Tauopathies | 3.6 | 108 | Citations (PDF) |
| 160 | Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy | 3.7 | 516 | Citations (PDF) |
| 161 | Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone | 14.3 | 154 | Citations (PDF) |
| 162 | Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis | 6.6 | 797 | Citations (PDF) |
| 163 | Calcium Entry and -Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons | 3.7 | 172 | Citations (PDF) |
| 164 | Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons | 35.1 | 557 | Citations (PDF) |
| 165 | Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models | 16.3 | 312 | Citations (PDF) |
| 166 | Neuropathologic substrates of Parkinson disease dementia | 6.6 | 398 | Citations (PDF) |
| 167 | Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathiesBrain, 2012, 135, 807-818 | 8.9 | 230 | Citations (PDF) |
| 168 | The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice | 3.7 | 318 | Citations (PDF) |
| 169 | Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion | 7.9 | 153 | Citations (PDF) |
| 170 | Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis | 7.9 | 101 | Citations (PDF) |
| 171 | A “Two-hit” Hypothesis for Inclusion Formation by Carboxyl-terminal Fragments of TDP-43 Protein Linked to RNA Depletion and Impaired Microtubule-dependent Transport | 2.3 | 93 | Citations (PDF) |
| 172 | The acetylation of tau inhibits its function and promotes pathological tau aggregation | 14.1 | 551 | Citations (PDF) |
| 173 | Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death | 12.8 | 1,182 | Citations (PDF) |
| 174 | Phiel et al. reply | 40.1 | 1 | Citations (PDF) |
| 175 | Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice | 9.1 | 330 | Citations (PDF) |
| 176 | Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI | 7.9 | 255 | Citations (PDF) |
| 177 | Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles | 2.3 | 499 | Citations (PDF) |
| 178 | Developing Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal Protein Targets | 6.7 | 98 | Citations (PDF) |
| 179 | <i>In Vivo</i>Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice | 3.7 | 288 | Citations (PDF) |
| 180 | Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration | 10.0 | 526 | Citations (PDF) |
| 181 | Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis | 7.9 | 270 | Citations (PDF) |
| 182 | Characterization of tau fibrillization in vitro | 0.7 | 53 | Citations (PDF) |
| 183 | Forebrain overexpression of α-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption | 4.1 | 30 | Citations (PDF) |
| 184 | Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects | 0.7 | 240 | Citations (PDF) |
| 185 | Aβ Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model | 3.6 | 170 | Citations (PDF) |
| 186 | TAR DNA-binding protein 43 in neurodegenerative disease | 9.2 | 367 | Citations (PDF) |
| 187 | Aggregation of α-Synuclein in S. cerevisiae is Associated with Defects in Endosomal Trafficking and Phospholipid Biosynthesis | 2.5 | 63 | Citations (PDF) |
| 188 | Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies | 2.3 | 289 | Citations (PDF) |
| 189 | Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | 6.6 | 1,719 | Citations (PDF) |
| 190 | Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies | 7.9 | 449 | Citations (PDF) |
| 191 | Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells | 7.7 | 749 | Citations (PDF) |
| 192 | Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies | 6.8 | 217 | Citations (PDF) |
| 193 | Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis | 3.6 | 259 | Citations (PDF) |
| 194 | Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis | 6.8 | 247 | Citations (PDF) |
| 195 | Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation | 2.3 | 488 | Citations (PDF) |
| 196 | Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies | 1.9 | 313 | Citations (PDF) |
| 197 | Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model | 12.8 | 1,631 | Citations (PDF) |
| 198 | Tau-mediated neurodegeneration in Alzheimer's disease and related disorders | 10.0 | 1,759 | Citations (PDF) |
| 199 | TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system | 7.9 | 56 | Citations (PDF) |
| 200 | Mechanisms of slow axonal transport of α‐synuclein | 0.7 | 0 | Citations (PDF) |
| 201 | Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis | 38.2 | 5,129 | Citations (PDF) |
| 202 | Pathological Heterogeneity of Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions Delineated by Ubiquitin Immunohistochemistry and Novel Monoclonal Antibodies | 3.6 | 281 | Citations (PDF) |
| 203 | Characterization of Two VQIXXK Motifs for Tau Fibrillizationin Vitro† | 2.9 | 152 | Citations (PDF) |
| 204 | Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery | 12.8 | 410 | Citations (PDF) |
| 205 | Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual | 7.9 | 11 | Citations (PDF) |
| 206 | Frontotemporal lobar degeneration 2005, , 481-493 | | 1 | Citations (PDF) |
| 207 | Transgenic animal models of tauopathies | 4.1 | 110 | Citations (PDF) |
| 208 | Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration | 12.8 | 263 | Citations (PDF) |
| 209 | More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases | 13.4 | 166 | Citations (PDF) |
| 210 | Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy | 7.9 | 35 | Citations (PDF) |
| 211 | Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† | 2.9 | 305 | Citations (PDF) |
| 212 | Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein | 38.2 | 747 | Citations (PDF) |
| 213 | Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies | 3.6 | 119 | Citations (PDF) |
| 214 | Secretion and Intracellular Generation of Truncated Aβ in β-Site Amyloid-β Precursor Protein-cleaving Enzyme Expressing Human Neurons | 2.3 | 72 | Citations (PDF) |
| 215 | Research on the Brain | 0.5 | 1 | Citations (PDF) |
| 216 | Signature Tau Neuropathology in Gray and White Matter of Corticobasal Degeneration | 3.6 | 131 | Citations (PDF) |
| 217 | Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein | 12.8 | 1,045 | Citations (PDF) |
| 218 | Amyloid binding ligands as Alzheimer’s disease therapies | 3.4 | 70 | Citations (PDF) |
| 219 | Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease | 6.6 | 212 | Citations (PDF) |
| 220 | Sporadic Pick's disease: A tauopathy characterized by a spectrum of pathological ? isoforms in gray and white matter | 6.6 | 133 | Citations (PDF) |
| 221 | Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases | 6.6 | 286 | Citations (PDF) |
| 222 | Tau and Axonopathy in Neurodegenerative Disorders | 3.7 | 114 | Citations (PDF) |
| 223 | Neurodegenerative Tauopathies | 12.3 | 2,272 | Citations (PDF) |
| 224 | A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly | 2.3 | 865 | Citations (PDF) |
| 225 | Frontotemporal dementia and tauopathy | 4.7 | 31 | Citations (PDF) |
| 226 | Lewy Body Pathology in Alzheimer's Disease | 2.5 | 138 | Citations (PDF) |
| 227 | Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons | 3.7 | 758 | Citations (PDF) |
| 228 | Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of α-Synuclein Permutations in Multiple System Atrophy | 1.9 | 133 | Citations (PDF) |
| 229 | Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons | 6.6 | 292 | Citations (PDF) |
| 230 | A new link between pesticides and Parkinson's disease | 12.4 | 64 | Citations (PDF) |
| 231 | Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment | 1.5 | 69 | Citations (PDF) |
| 232 | A Distinct ER/IC γ-Secretase Competes with the Proteasome for Cleavage of APP | 2.9 | 70 | Citations (PDF) |
| 233 | Functional synapses are formed between human NTera2 (NT2N, hNT) neurons grown on astrocytes 1999, 407, 1-10 | | 126 | Citations (PDF) |
| 234 | [6] Purification of paired helical filament tau and normal tau from human brain tissue | 1.0 | 46 | Citations (PDF) |
| 235 | Accumulation of Intracellular Amyloid-β Peptide (Aβ 1–40) in Mucopolysaccharidosis Brains | 1.9 | 54 | Citations (PDF) |
| 236 | Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia | 13.7 | 262 | Citations (PDF) |
| 237 | Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors | 7.9 | 31 | Citations (PDF) |
| 238 | RNA sequestration to pathological lesions of neurodegenerative diseases | 7.9 | 113 | Citations (PDF) |
| 239 | Lewy Bodies Contain Altered α-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes | 3.6 | 454 | Citations (PDF) |
| 240 | Unique Alzheimer's Disease Paired Helical Filament Specific Epitopes Involve Double Phosphorylation at Specific Sites | 2.9 | 145 | Citations (PDF) |
| 241 | α-Synuclein in Lewy bodies | 40.1 | 6,982 | Citations (PDF) |
| 242 | Neurofilament reassembly in vitro: biochemical, morphological and immuno-electron microscopic studies employing monoclonal antibodies to defined epitopes | 2.5 | 39 | Citations (PDF) |
| 243 | Individual neurofilament subunits reassembled in vitro exhibit unique biochemical, morphological and immunological properties | 2.5 | 32 | Citations (PDF) |
